Page 29 - Visual Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail IMAGE: Michael A. Kass, MD, (right) led the national Ocular Hypertension Treatment Study to determine whether lowering elevated eye pressure in patients might prevent vision loss from glaucoma. Kass and colleague... view more  Credit: Washington University School of Medicine More than 20 years after the launch of a landmark clinical trial, follow-up examinations and analyses found that not all patients with elevated eye pressure need pressure-lowering treatment to prevent vision loss from glaucoma. When the study was launched, it was universally accepted that all patients wi...

Landmark study shows most patients with elevated pressure don’t go on to lose vision April 15, 2021 SHARE Michael A. Kass, MD, (right) led the national Ocular Hypertension Treatment Study to determine whether lowering elevated eye pressure in patients might prevent vision loss from glaucoma. Kass and colleague Mao O. Gordon, PhD, recently completed follow-up studies on patients 20 years after the start of the original study and found that not all patients with elevated eye pressure need pressure-lowering treatment to prevent vision loss from glaucoma. (Photo: School of Medicine) More...

Punch Newspapers Sections Lara Adejoro Vice-President, Ophthalmological Society of Nigeria and Consultant Ophthalmologist at The Eye Doctors Clinic, Dr. Abiola Oyeleye, says some glaucoma eye drops can ‘minimally increase’ the incidence of sexual dysfunction and impotence. He, however, added that the benefits of the eye drops far outweigh the consideration of not using them. Oyeleye spoke in reaction to a study published by the National Centre for Biotechnology Information on the correlation in severity between glaucoma and erectile dysfunction. The study states that there is a positive a...

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease 2019 (COVID-19), is a novel pathogen that emerged in December 2019 in China. Since then, it has spread globally to over 191 countries and territories, infecting more than 96.82 million people and claiming over 2 million lives. As the virus continues to spread and new highly infectious variants emerge, understanding the complex pathogen-host interplay is urgently needed to effectively control its spread. ...

Posted on 553 Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity. Serving in key leadership roles on Aviceda’s Executive Leadersh...